Data to be Presented on Ongoing Natesto Spermatogenesis Study, Study Evaluating the Effect of Natesto Nasal Testosterone on Male Fertility Parameters
ENGLEWOOD, CO / ACCESSWIRE / March 14, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that the company and its research collaborators will make multiple Natesto® presentations at two upcoming scientific conferences.
The company will present at ENDO 2019, the 101st annual scientific meeting of the Endocrine Society, and at the 2nd annual meeting of the Androgen Society. Both meetings will be held in New Orleans, Louisiana. The Androgen Society meeting will be held March 21-22, 2019, and ENDO 2019 will be held March 23-26, 2019.
- 2nd Annual Androgen Society Meeting - New Orleans, LA (March 21-22, 2019)
Gerwin Westfield, PhD, Director of Medical Affairs at Aytu BioScience, will present on Natesto during the ''New and Emerging Therapies'' session. Dr. Westfield will present on March 21, 2019 at 3:30 PM.
Ranjith Ramasamy, MD, Director of Reproductive Urology at the University of Miami School of Medicine, will present data from the ongoing Natesto Spermatogenesis Study. Dr. Ramasamy will present on March 22, 2019 at 9:30 AM.
- ENDO 2019 - New Orleans, LA (March 23-26, 2019)
Thomas Masterson, MD (Department of Urology, University of Miami School of Medicine) will be the presenting author from Dr. Ramasamy’s group. Dr. Masterson will present data from the ongoing Natesto Spermatogenesis Study. He will present on March 24, 2019 at 2:00 PM.
About Aytu BioScience
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"). Aytu also has exclusive U.S. and Canadian rights to ZolpiMist™, an FDA-approved, commercial-stage prescription sleep aid indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Aytu recently acquired exclusive U.S. commercial rights to Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. Tuzistra XR is a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an extended-release oral suspension. Additionally, Aytu is developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside of the U.S. where it is a CE Marked, Health Canada cleared, Australian TGA approved, Mexican COFEPRAS approved product, and Aytu is planning U.S.-based clinical trials in pursuit of 510k de novo medical device clearance by the FDA. Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com.
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the risks relating to the timing and results of the Natesto spermatogenesis study and other clinical studies, gaining market acceptance of our products both domestically and internationally, obtaining reimbursement by third-party payors, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future revenue growth, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of Aytu BioScience, Inc.'s Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.
Contact for Investors:
SOURCE: Aytu BioScience, Inc.
View source version on accesswire.com: